Clinical-study of multiple-myeloma in the elderly

Area of Science:

• Hematology
• Oncology
• Geriatrics

Background:

• Multiple myeloma (MM) is a hematologic malignancy primarily affecting older adults.
• Treatment strategies for elderly MM patients require careful consideration of efficacy and toxicity.
• The role of alpha-interferon (IFN) as an adjunct therapy in MM warrants investigation.

Purpose of the Study:

• To evaluate the efficacy of alpha-interferon (IFN) in elderly patients with multiple myeloma (MM).
• To compare treatment response rates and survival times in MM patients with and without IFN therapy.

Main Methods:

• A prospective study involving 120 elderly patients (≥65 years) with MM.
• Patients received chemotherapy, with a subgroup treated with alpha-interferon (IFN) (n=33) and a control group without IFN (n=70).
• Data collected included response rates (CR+PR), overall efficacy (CR+PR+MR), and 50% survival time.

Main Results:

• Overall response rate (CR+PR) was 24.0% for all patients.
• Response rates were similar between the IFN group (24.2%) and the non-IFN group (25.7%).
• Efficacy rates (CR+PR+MR) were 78.8% (all), 81.8% (IFN), and 78.8% (non-IFN).
• The 50% survival time was 31 months overall, 44 months with IFN, and 38 months without IFN.

Conclusions:

• Alpha-interferon (IFN) did not demonstrate a significant improvement in response rates for elderly multiple myeloma (MM) patients.
• Survival times showed no statistically significant difference between patients treated with or without IFN.
• These findings suggest that IFN may not offer a substantial benefit as an adjunct therapy in this patient population.